Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Recommendation of "Buy" by Analysts

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has earned an average recommendation of "Buy" from the six research firms that are covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $8.20.

Several brokerages have recently issued reports on GANX. HC Wainwright reiterated a "buy" rating and set a $8.00 price target on shares of Gain Therapeutics in a report on Monday, May 19th. Scotiabank began coverage on Gain Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $12.00 price target for the company. Finally, Chardan Capital reiterated a "buy" rating and set a $6.00 price target on shares of Gain Therapeutics in a report on Friday, March 28th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Sprott Inc. bought a new position in shares of Gain Therapeutics in the 4th quarter valued at approximately $30,000. Benedict Financial Advisors Inc. bought a new position in shares of Gain Therapeutics in the 4th quarter valued at approximately $35,000. Bridgeway Capital Management LLC bought a new position in shares of Gain Therapeutics in the 4th quarter valued at approximately $65,000. Northern Trust Corp raised its stake in shares of Gain Therapeutics by 88.2% in the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company's stock valued at $183,000 after acquiring an additional 39,642 shares in the last quarter. Finally, Jones Financial Companies Lllp raised its stake in shares of Gain Therapeutics by 83.6% in the 4th quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company's stock valued at $212,000 after acquiring an additional 44,750 shares in the last quarter. 11.97% of the stock is owned by institutional investors.

Gain Therapeutics Stock Up 0.3%

NASDAQ GANX traded up $0.01 during trading on Wednesday, reaching $1.80. 72,466 shares of the company's stock were exchanged, compared to its average volume of 311,633. The firm has a market capitalization of $53.20 million, a PE ratio of -1.64 and a beta of 0.17. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04. Gain Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $3.19. The company's fifty day simple moving average is $1.89 and its 200-day simple moving average is $1.99.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). Sell-side analysts predict that Gain Therapeutics will post -1 EPS for the current year.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.